ABBV AbbVie Inc

61.79
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet primary endpoints - April 19, 2017.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Approved November 13, 2013.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved February 12, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved July 19, 2014.
Imbruvica
Deletion 17p
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved January 29, 2015 - PCYC
IMBRUVICA
Waldenström’s Macroglobulinemia
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12
Progressive supranuclear palsy (PSP)
Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABBV-8E12
Alzheimer's disease
Phase 3 interim data possibly due 2H 2017.
Imbruvica - PHOENIX
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial initiated July 2016.
Venetoclax
Relapsed or refractory multiple myeloma
Phase 3 data due 2017.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 trial to commence 2017.
Venclexta
Follicular lymphoma (FL)
Phase 3 trial to commence 2017.
Venclexta
First-line Diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial to commence 2017.
Rova-T
First-line small cell lung cancer (SCLC) maintenance
Phase 3 trial to commence 1H 2017.
Risankizumab
Crohn’s Disease
Phase 3 data due by the end of 2017.
Risankizumab
Psoriasis
Phase 3 initiated by partner Abbvie in January 2016. Data due 4Q 2017.
Elagolix
Uterine Fibroids
sNDA filing announced April 4, 2017. Assuming priority review would render a PDUFA date of September 4, 2017. Awaiting confirmation of official PDUFA date.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Elagolix
Endometriosis
Phase 3 trial to commence 2017.
ABT-494
Psoriatic Arthritis
Phase 3 trial initiated January 2016.
ABT-494 - SELECT-NEXT
Rheumatoid arthritis
Phase 2b data due 1H 2017.
Risankizumab
Psoriatic Arthritis
Phase 2b data due 1H 2017.
ABT-494
Crohn’s Disease
Phase 2b data due 2017.
ABT-494
Atopic Dermatitis
Phase 2 pivotal data due 1H 2017.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica
Marginal zone lymphoma
Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)

Latest News

  1. Better Buy: AbbVie Inc. vs. Pfizer
  2. Cramer's lightning round: This drug stock is simply not good enough for your portfolio
  3. AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
  4. What's in Store for AbbVie (ABBV) this Earnings Season?
  5. Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study
  6. AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference
  7. Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
  8. AbbVie, Inc. – Value Analysis (NYSE:ABBV) : April 20, 2017
  9. Failure Of Abbvie's Cancer Drug Hasn't Hurt The Stock
  10. AbbVie's PARP Inhibitor Comes Up Empty
  11. AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
  12. AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
  13. AbbVie cancer drug fails two late-stage trials
  14. AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : April 19, 2017
  15. Top 4 Medicinal Marijuana Stocks to Watch for 2017
  16. Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs
  17. Is AbbVie a Great Dividend Stock for Your Portfolio?
  18. The Better Big Pharma Stock: AbbVie or Gilead?
  19. High-Yield Healthcare Investments You Can Buy Right Now
  20. Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug?